General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews

The growing demand for improved pain treatments together with expanding legalization of, and access to, cannabinoids, cannabis, and cannabis-based medicines has intensified the focus on risk–benefit considerations in pain management. Given limited harms data from analgesic clinical trials, we conducted an overview of systematic reviews focused on all harms possibly relevant to patients receiving cannabinoids for pain management. This PROSPERO-registered, PRISMA-compliant systematic overview identified 79 reviews, encompassing over 2200 individual reports about psychiatric and psychosocial harms, cognitive/behavioral effects, motor vehicle accidents, cardiovascular, respiratory, cancer-related, maternal/fetal, and general harms. Reviews, and their included studies, were of variable quality. Available evidence suggests variable associations between cannabis exposure (ranging from monthly to daily use based largely on self-report) and psychosis, motor vehicle accidents, respiratory problems, and other harms. Most evidence comes from settings other than that of pain management (eg, nonmedicinal and experimental) but does signal a need for caution and more robust harms evaluation in future studies. Given partial overlap between patients receiving cannabinoids for pain management and individuals using cannabinoids for other reasons, lessons from the crisis of oversupply and overuse of opioids in some parts of the world emphasize the need to broadly consider harms evidence from real-world settings. The advancement of research on cannabinoid harms will serve to guide optimal approaches to the use of cannabinoids for pain management. In the meantime, this evidence should be carefully examined when making risk–benefit considerations about the use of cannabinoids, cannabis, and cannabis-based medicine for chronic pain.

Read the full article here: https://journals.lww.com/pain/Fulltext/2021/07001/General_risks_of_harm_with_cannabinoids,_cannabis,.7.aspx

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Related Posts

Sentinel Surveillance of Substance-Related Poisonings in Canada: Spotlight on Cannabis

Substance-related poisonings and injuries in Canada have received increasing attention in recent years due to emerging public health concerns, such as the opioid overdose crisis, the introduction of synthetic cannabinoids to the illicit market and the emergence of electronic cigarettes/vaping products on the Canadian market. Furthermore, there has been a general increase in substance-related hospitalizations

Changes in Rates of Hospitalizations due to Cannabis Harms in Ontario, Canada Before the Legalization of Nonmedical Cannabis: Retrospective Population-level Study Between 2003 and 2017

There are distinct patterns of hospitalizations due to cannabis harms in different priority populations. Young women aged 15 to 24 are a key demographic that is disproportionately burdened with a rapid increase in hospitalizations due to cannabis harms. Jurisdictions considering new approaches to cannabis control policy and addiction services should consider the rising burden of

Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”

Nonmedical (“recreational”) cannabis use and cannabis laws have changed over the past two decades in the United States (1) and the rest of the world (2). Increasing use, especially among the young, coupled with the increasing potency of cannabis (higher delta-9-tetrahydrocannabinol [THC] content) during this period (3), has raised concerns about the long-term health impact

Scroll to Top